Aggressive progressive pleuroparenchymal fibroelastosis developed long after allogenic hematopoietic stem cell transplantation
Key Clinical Message The typical pleuroparenchymal fibroelastosis (PPFE) after hematopoietic stem cell transplantation (HSCT) is characterized by late‐onset progressive pulmonary complication within 5 years. PPFE shows a poor prognosis without definitive standard care other than lung transplantation...
Main Authors: | Osamu Imataki, Makiko Uemura |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | Clinical Case Reports |
Subjects: | |
Online Access: | https://doi.org/10.1002/ccr3.8415 |
Similar Items
-
Diagnosis of pleuroparenchymal fibroelastosis: A review
by: Cuneyt Tetikkurt, et al.
Published: (2022-10-01) -
Pleuroparenchymal fibroelastosis in idiopathic pulmonary fibrosis: Survival analysis using visual and computer-based computed tomography assessment
by: Eyjolfur Gudmundsson, et al.
Published: (2021-08-01) -
Transbronchial cryobiopsy for diagnosis of pleuroparenchymal fibroelastosis
by: Abdulrahman Hakami, et al.
Published: (2020-01-01) -
Pleuroparenchymal fibroelastosis secondary to autologous peripheral blood stem cell transplantation: A case report
by: Ayaka Egashira, et al.
Published: (2023-01-01) -
Clinical and radiological characteristics of patients with late-onset severe restrictive lung defect after hematopoietic stem cell transplantation
by: Ho Namkoong, et al.
Published: (2017-09-01)